Zobrazeno 1 - 10
of 32
pro vyhledávání: '"J.G. Duero Posada"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
E. Rodenas-Alesina, J.M. Amadio, S. Superina, S. Kozuszko, K. Tsang, A. Simard, N. Aleksova, J. Kobulnik, C. Fan, H.C. Wijeysundera, H.J. Ross, M.A. McDonald, J.G. Duero-Posada, Y. Moayedi
Publikováno v:
The Journal of Heart and Lung Transplantation. 41:S128
Autor:
J.J. Teuteberg, F. Billia, B. Mueller, S. Fan, H.J. Ross, Kiran K. Khush, J.G. Duero Posada, Yasbanoo Moayedi
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S109-S110
Publikováno v:
Canadian Journal of Cardiology. 37:S61
Autor:
Heather J. Ross, Ana C. Alba, Yasbanoo Moayedi, Chun-Po Steve Fan, Farid Foroutan, J. Stehlik, C. McGuinty, Adriana Luk, J.G. Duero Posada, Natasha Aleksova
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S112
Purpose Predicted heart mass (PHM) was neither derived nor validated in an obese population. Our objectives were to determine survival according to size mismatch defined by actual PHM and recalculated PHM using ideal body weight (IBW) in obese recipi
Autor:
F. Billia, Heather J. Ross, Vivek Rao, D.H. Brahmbhatt, Harry Rakowski, J.K. Vishram-Nielsen, Daiyoon Lee, Yasbanoo Moayedi, J.G. Duero Posada, M. Alhussein
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S185
Purpose There is controversy over the use of durable left ventricular assist devices (LVADs) in supporting patients with hypertrophic cardiomyopathy (HCM) and advanced heart failure. HCM patients have smaller left ventricular (LV) dimensions and are
Autor:
Heather J. Ross, Yasbanoo Moayedi, F. Billia, K. Black, S. Fan, J.G. Duero Posada, K. Runeckles, J. Stehlik, Jennifer M. Amadio, L. Carey, S. Kozuzsko
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S110
Purpose Donors with a history of heavy alcohol use (DHAU) may have subclinical cardiomyopathy, resulting in poor outcomes after heart transplantation (HT). We sought to assess short-and long-term mortality, graft failure and cardiac allograft vasculo
Autor:
Yasbanoo Moayedi, Heather J. Ross, E.J. Henricksen, S. Fan, E. Somerset, J.J. Teuteberg, F. Billia, J.G. Duero Posada, Sharon Chih, Barbara S. Doumouras
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S40
Purpose Cardiac Allograft Vasculopathy (CAV) is the leading cause of graft dysfunction in heart transplantation (HT). Identifying CAV profiles is critical in determining the intensity of surveillance required to appropriately prevent and treat this c
Autor:
N. Aleksova, F. Billia, F. Foroutan, T.A. Buchan, J. Bielecki, J.K. Vishram-Nielsen, J. Alvarez, A. Kinsella, K. Clark, A. Zhu, K. Lau, C. McGuinty, T. Francis, A. Stanimirovic, A. Malik, J.G. Duero Posada, E. Fan, V. Rac, V. Rao, H.J. Ross, A.C. Alba
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S418-S419
Autor:
Michael McDonald, Ana C. Alba, S. Kozuszko, Heather J. Ross, Abdullah Malik, O. Calvillo Argüelles, Farid Foroutan, Anne I. Dipchand, J.G. Duero Posada
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S283-S284
Purpose Heart re-transplantation (HRT) is the definitive treatment for end stage cardiac allograft vasculopathy (CAV) and refractory primary graft dysfunction (PGD). According to the ISHLT registry, the median survival of patients who underwent HRT b